Comparison of efficacy and safety of pioglitazone versus metformin for moderate-to-severe chronic plaque psoriasis in patients with prediabetes or newly-diagnosed diabetes who have never taken anti-diabetic agents: a parallel, randomized, open-label, prospective study

Comparison of efficacy and safety of pioglitazone versus metformin for moderate-to-severe chronic plaque psoriasis in patients with prediabetes or newly-diagnosed diabetes who have never taken anti-diabetic agents: a parallel, randomized, open-label,

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190724005

Enrollment

Registered

2019-07-24

Start date

2019-06-05

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis prediabetes diabetes mellitus plaque psoriasis prediabetes diabetes mellitus

Interventions

Pioglitazone (45 mg daily&#44

fixed dose),Metformin (500 mg daily&#44

fixed dose)

Experimental Drug,Experimental Drug

Pioglitazone group,Metformin group

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: -Minimum 18 Years -Extensive chronic plaque-type psoriasis (at least 5% body surface area involvement) -Prediabetes (fasting blood glucose 100-125 mg/dL or HbA1C 5.7-6.4%) or diabetes mellitus (fasting blood glucose > 126 mg/dL or HbA1C > 6.5)

Exclusion criteria

Exclusion criteria: -Pregnancy or lactation -History of pioglitazone or metformin allergy -Congestive heart failure (NYHA class III or IV) or ischemic heart disease -History of diabetic ketoacidosis -Impaired hepatic function (>2.5 times upper range limit) -Impaired renal function (estimated glomerular filtration rate 30 kg/m2) -Alcoholism -History of bladder cancer -History of bony fracture

Design outcomes

Primary

Measure	Time frame
Psoriasis Area Severity Index (PASI) week 0, 2, 4, 8, 12 PASI scores	—

Secondary

Measure	Time frame
Adverse drug reactions week 0, 2, 4, 8, 12 clinical follow-up	—

Contacts

Public ContactWeeratian Tawanwongsri

Ramathibodi

weeratian.ta@gmail.com0895966668

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026